Brain Metastases (Secondary Brain Tumors) — Diagnosis, Treatment & Prognosis

Most readers benefit from the Quick Summary plus the sections on How Brain Metastases Cause Symptoms, Treatment Strategy, and Prognosis. Other sections provide deeper clinical context and decision-making insight.

What Are Brain Metastases?

Brain metastases are the most common type of brain tumors in adults. They occur when cancer cells spread to the brain from a malignant tumor elsewhere in the body. For this reason, brain metastases are also called secondary brain tumors, in contrast to primary brain tumors that originate from brain tissue itself.

It is estimated that 20–40% of all patients with systemic cancer will develop brain metastases during the course of their disease, depending on the primary tumor type and advances in systemic therapy. As cancer survival improves, the incidence of brain metastases continues to rise.

Where Do Brain Metastases Come From?

Brain metastases most commonly originate from the following primary cancers:

• Lung cancer – approximately 40–50% of all brain metastases
• Breast cancer – approximately 15–25%
• Melanoma – approximately 5–20% (with a particularly high biological tendency to spread to the brain)
• Renal cell carcinoma – approximately 5–10%
• Colorectal cancer – approximately 3–5%
• Other cancers (including ovarian, bladder, head and neck, and unknown primaries) account for a smaller proportion

In 20–30% of patients, brain metastases are diagnosed before the primary cancer is known. In these cases, the brain lesion may be the first manifestation of an underlying systemic malignancy, and further diagnostic workup is required to identify the site of origin.

Image: Brain metastasis originating from lung cancer

Why Brain Metastases Are Different from Primary Brain Tumors

Brain metastases behave differently from primary brain tumors because they represent systemic cancer involvement of the brain, not a disease limited to the central nervous system. Even when brain metastases are successfully removed or controlled locally, the underlying malignant disease elsewhere in the body often continues to determine overall prognosis.

Hematogenous Spread and Brain Location

Brain metastases most commonly reach the brain through hematogenous spread. Tumor cells circulate systemically and tend to lodge at the gray–white matter junction, where abrupt changes in vessel diameter slow blood flow and facilitate tumor cell deposition. This explains why metastases are frequently located in the cerebral hemispheres and why they often appear as well-demarcated lesions surrounded by extensive edema.

At the time of diagnosis, approximately 60–70% of patients have multiple brain metastases, while 30–40% present with a single lesion. This high rate of multiplicity reflects the systemic nature of malignant disease and distinguishes brain metastases from most primary brain tumors, which are usually solitary at presentation.

The anatomical distribution of brain metastases follows regional cerebral blood flow. About 80% are located in the cerebral hemispheres, 15–20% in the cerebellum, and 3–5% in the brainstem. In adults, metastasis is the most common malignant lesion of the cerebellum. For this reason, when an enhancing lesion is detected in the cerebellum on MRI, metastatic disease must be excluded first, even in patients without a known primary cancer.

---

How Brain Metastases Develop and Damage the Brain

Why Small Metastases Can Cause Severe Symptoms

Once metastatic cells establish themselves within the brain, they disrupt the blood–brain barrier, causing fluid to leak from the vessels into the surrounding tissue. This results in vasogenic edema, which creates a cascade of damage: the swelling physically pushes brain cells away from their capillary blood supply and compresses small vessels, severely impairing local circulation and nutrient delivery. Because the brain is enclosed within the rigid, unyielding skull, this expanding edema quickly leads to a rise in intracranial pressure (ICP). As the pressure builds, the tumor and edema can push the brain’s delicate structures across the center line (midline shift) or force them into narrow openings in the skull, a life-threatening process known as herniation that can lead to sudden coma or death. This elevated pressure further compromises global brain circulation, creating a dangerous cycle of oxygen deprivation and tissue dysfunction. In tight spaces like the posterior fossa, even a small metastasis can cause rapid neurological collapse by compressing the brainstem or obstructing cerebrospinal fluid pathways, leading to acute hydrocephalus.

These mechanisms explain why patients may deteriorate rapidly and why symptom control often requires urgent intervention.

Increased Intracranial Pressure (ICP)

As edema and mass effect increase, intracranial pressure (ICP) may rise. Elevated ICP can lead to:

• worsening headache
• nausea and vomiting
• reduced level of consciousness
• life-threatening brain herniation if untreated

This is one of the reasons why symptomatic brain metastases often require immediate local treatment, regardless of the long-term oncological plan.

Hemorrhage and Acute Neurological Deterioration

Some metastases—particularly those from melanoma, renal cell carcinoma, choriocarcinoma, and certain lung cancers—have a strong tendency to bleed. Intratumoral hemorrhage can cause sudden neurological decline and may convert a previously stable situation into a neurosurgical emergency.

Systemic and Immune-Mediated Effects

Neurological dysfunction in cancer patients is not always caused directly by visible metastases. Immune-mediated processes or systemic complications—such as metabolic failure, infections, or treatment toxicity—can significantly worsen brain function. (See the section below on Paraneoplastic Syndromes for more detail on how cancer affects the nervous system from a distance).

Why Patients May Die Even When Brain Metastases Are Locally Controlled

Modern neurosurgery, stereotactic radiosurgery (Gamma Knife, CyberKnife), and radiotherapy can sometimes eliminate all visible brain metastases on MRI. However, local brain control does not necessarily mean the cancer has been cured, nor does it guarantee long-term survival. Major guidelines emphasize that overall outcome is often driven by the systemic disease trajectory, even when intracranial lesions are controlled.

1) Micrometastatic Disease and “Invisible” Systemic Progression

A patient may have no large tumors detectable on routine imaging, yet still have microscopic dissemination (micrometastases) throughout the body. This can progressively impair organ function without forming a single “dominant” mass.

Examples include:

• diffuse liver infiltration causing liver failure before a discrete bulky lesion is seen,
• bone marrow infiltration causing progressive cytopenias (anemia, infections, bleeding),
• lymphangitic spread in the lungs impairing oxygenation without a large lung mass.

In other words, cancer can behave as a systemic biological process, not only as a collection of visible tumors.

2) New CNS Seeding Despite Local Control of Known Lesions

Even if treated lesions remain controlled, the underlying systemic cancer may continue to shed tumor cells, leading to new brain metastases or diffuse CNS involvement over time. A 2023 analysis of causes of death in brain metastasis patients suggests that neurological decline is often linked to ongoing CNS seeding rather than failure of local growth control of the original lesions.

3) Leptomeningeal Disease (LM) and Diffuse CNS Spread

Some patients develop leptomeningeal metastasis, which occurs when cancer cells escape the solid tumor and spread into the meninges (the thin protective layers or ‘linings’ that wrap around the brain and spinal cord) and the cerebrospinal fluid (CSF) that bathes them. Instead of forming a single solid lump that is easy to see on a scan, the cancer spreads like a ‘thin coat of paint’ or a ‘dusting of snow’ over the entire surface of the brain and its nerves. This can cause rapid neurological deterioration because the cancer cells circulate everywhere the fluid goes, potentially affecting multiple nerves at once and blocking fluid drainage. This is one of the key ‘hidden’ reasons families experience a sudden decline; the solid tumors on previous scans may look stable or ‘good,’ but this invisible fluid-based spread is causing new and severe damage.

4) Paraneoplastic Neurologic Syndromes (Immune-Mediated Injury)

Some neurological deterioration is not caused by tumor tissue at all, but by immune-mediated remote effects of cancer, known as paraneoplastic neurologic syndromes.

These can involve:

• limbic encephalitis (confusion, seizures, memory loss),
• cerebellar degeneration (rapid severe ataxia),
• myelopathy,
• peripheral and autonomic neuropathies (including dangerous blood pressure/heart rate instability).

Importantly: paraneoplastic syndromes may occur when the cancer burden is small or not yet clearly visible, and they can progress independently of “tumor size.” Modern diagnostic criteria and practical management frameworks emphasize exactly this challenge.

5) Cancer-Related Hypercoagulability (Blood Clots)

Cancer increases the risk of venous thromboembolism (DVT/PE) and other thrombotic events. A patient with stable imaging can still die suddenly from pulmonary embolism or suffer disabling strokes or organ infarctions due to the prothrombotic state of malignancy. (This is one of the most common “unexpected” catastrophic events in oncology.)

6) Infections, Metabolic Failure, and Treatment-Related Toxicity

Even without bulky tumors, patients may die from:

• severe infection/sepsis (especially with chemotherapy-related immunosuppression or marrow involvement),
• renal failure, electrolyte derangements, malnutrition/cachexia,
• treatment-related toxicity (systemic therapy, immunotherapy, steroid complications).

Steroids, for example, may be necessary for edema/ICP symptom control, but they also increase risks such as infection, myopathy, diabetes, delirium, and GI complications—one reason guidelines stress careful indication and tapering.

The Key Message for Patients and Families

Local brain control is extremely valuable because it can:

• prevent fatal intracranial pressure crises,
• reduce seizures and neurological disability,
• preserve independence and quality of life.

Evo ispravljenog i „ispeglanog“ završetka te sekcije. Izbacio sam duplirane delove i spojio rečenice u logičan, snažan zaključak:

Local brain control is extremely valuable because it can prevent fatal intracranial pressure crises, reduce seizures, and preserve neurological function. However, overall survival is usually determined by the behavior of the primary cancer and the extent of extracranial disease. Survival may still be limited by systemic cancer biology, diffuse microscopic spread, immune-mediated complications (paraneoplastic syndromes), leptomeningeal disease, thrombosis, infection, or metabolic failure. This is why brain metastasis treatment is best approached as a comprehensive multidisciplinary strategy, rather than just a ‘brain procedure plan.

Symptoms of Brain Metastases

Common symptom patterns include:

• Headache (often from edema and pressure effects)
• Seizures
• Focal neurological deficits depending on the metastasis location (weakness, speech difficulty, vision changes, imbalance)
• Cognitive or behavioral changes
  Symptoms depend more on location, edema, and mass effect than on the primary cancer type.

Diagnostic Workup and Imaging Strategy

Diagnosis typically relies on:

• MRI of the brain with contrast (preferred for sensitivity and surgical/radiation planning)
• CT when urgent evaluation is needed (e.g., acute neurological deterioration, suspected hemorrhage)
• Metastasis biopsy and tissue diagnosis when imaging is atypical, when the primary tumor is unknown, or when pathology will change the treatment plan
• Systemic staging is performed to assess the extent of extracranial disease and to confirm or identify the primary malignancy when needed. This typically includes contrast-enhanced CT of the chest, abdomen, and pelvis. PET-CT may be considered in selected cases, particularly when a more comprehensive assessment of metastatic spread is required for treatment planning or when conventional imaging is inconclusive. Tumor markers can support systemic evaluation in specific clinical contexts but are primarily used to monitor disease progression or treatment response rather than as standalone diagnostic tools.

Image: Contrast-enhanced brain MRI showing multiple, well-circumscribed metastatic brain tumors in both hemispheres, appearing as bright lesions with surrounding edema.

When Brain Metastases Are the First Sign of Cancer

If a brain metastasis is discovered before the primary cancer is known, the priority becomes:

1. stabilizing urgent neurological risks (edema/ICP, seizures, hemorrhage), and
2. performing a structured systemic workup to identify the primary tumor and define a treatment strategy.

---

Differential Diagnosis of Brain Metastases

• Primary brain tumor (glioblastoma, astrocytoma) – usually a single tumor that grows into surrounding brain tissue, not just pushing it aside
• Brain abscess (infection) – can look similar on scans but is caused by bacteria or infection and often comes with fever
• Primary CNS lymphoma – a type of cancer of immune cells in the brain, often located deep near the ventricles
• Demyelinating disease (e.g., multiple sclerosis) – inflammatory lesions that can mimic tumors, especially in younger patients
• Subacute stroke (infarction) – damaged brain tissue from reduced blood flow that can temporarily resemble a tumor on imaging
• Radiation necrosis – tissue damage after previous radiotherapy that can look like tumor recurrence
• Vascular lesions (cavernoma) – abnormal blood vessels that may appear as a mass but behave differently from tumors
• Meningioma – usually a benign tumor arising from the brain covering (dura), often attached to the skull

In many patients, the diagnosis is relatively straightforward when there is a known primary cancer or when multiple lesions are present on imaging.

---

How Neurosurgeons Decide on Surgery for Brain Metastases

There is no single rule that applies to everyone. Decisions about surgery for brain metastases are never based on brain imaging alone. In real clinical practice, the expected prognosis of the primary cancer—usually defined by the treating oncologist—is one of the most important factors influencing whether surgery is recommended.

Modern guidelines describe surgery as a reasonable option in selected patients, particularly when a metastasis causes significant mass effect, rapid neurological deterioration, or when tissue diagnosis is required. However, neurosurgical intervention is generally considered meaningful only if the patient’s overall cancer prognosis allows sufficient time to benefit from local brain control.

In most cases, the neurosurgeon relies on information provided by the oncology team regarding:

• the type of primary cancer,
• its biological aggressiveness,
• Status of the primary tumor, presence of other metastases, functional state of the affected organs, and comorbidities.
• available systemic treatment options,
• and the expected survival trajectory based on current oncological protocols.

A neurosurgical recommendation is therefore based on the combined picture of:

• Expected prognosis of the primary cancer, as assessed by the treating oncologist
• Neurological status and urgency (e.g., declining consciousness, focal deficits)
• Tumor size and mass effect, including edema and risk of herniation
• Tumor location and surgical risk
• Number of brain metastases, but never as the sole deciding factor
• Extent and control of systemic disease
• Availability and timing of radiosurgery or radiotherapy
• Expected quality-of-life benefit, not merely radiological control

In practical terms, two patients with identical brain MRI findings may receive very different surgical recommendations if their primary cancer prognosis differs. Surgery may be appropriate in a patient with a controlled or treatable systemic malignancy, while the same procedure may offer little benefit in a patient with rapidly progressive, therapy-resistant disease.

Because so many variables influence whether and how to operate on one or more brain metastases, extensive neurosurgical experience is essential. It requires a high level of clinical judgment to correctly assess the combination of these factors, design a tailored surgical strategy, and execute the plan with precision.

---

Why Metastasis Count Alone Does Not Decide Surgery

The number of brain metastases matters—but it does not determine the treatment plan by itself. Some patients may undergo surgery for multiple lesions if they are surgically accessible and if the expected neurological and functional benefit is high. Conversely, a single metastasis may not be operated on if it is located in a high-risk area, if radiosurgery offers equivalent local control with lower risk, or if systemic disease status makes surgery unlikely to improve overall outcome.

---

Why Two Neurosurgeons May Recommend Different Plans — Operate or Not?

Brain metastasis care often involves clinical gray zones where more than one approach is medically reasonable. Differences in recommendations do not necessarily indicate an error, but reflect how complex decisions are made in real clinical practice.

Surgical Risk vs Expected Neurological Benefit

One neurosurgeon may prioritize maximal tumor removal, while another may focus on preserving neurological function, especially when the lesion is located in a high-risk area.

Availability and Role of Radiosurgery

In some centers, stereotactic radiosurgery (SRS) is more readily integrated into treatment strategies, which may lead to recommendations that favor non-surgical approaches over open surgery.

Urgency of Symptom Progression

If a patient is experiencing rapid neurological deterioration, surgery may be recommended more strongly. In more stable cases, less invasive options may be considered.

Interpretation of Systemic Disease and Prognosis

Decisions are heavily influenced by the primary cancer biology, extent of systemic disease, and expected survival. The same brain finding may be treated differently depending on the overall oncological context.

This variability is one of the main reasons why multidisciplinary evaluation—and in selected cases, a second opinion—can be valuable..

---

Multidisciplinary Treatment Planning: Primary-Cancer Protocols First

Brain metastases are not treated in isolation. In most cases, a multidisciplinary team plan is essential because:

• systemic cancer therapy is driven by the primary tumor type and molecular profile, and
• local brain control (surgery/SRS/WBRT) must be sequenced safely with systemic therapy.

Major guidelines emphasize that symptomatic brain metastases should receive local therapy and that deferral of local therapy for asymptomatic lesions should only occur when specifically recommended by evidence-based protocols.

Overview of Treatment Modalities for Brain Metastases

Most treatment plans combine two categories:

1. Symptom and risk control (edema/ICP, seizures, hemorrhage risk)
2. Local control (surgery and/or radiotherapy)
3. Systemic therapy (chosen according to primary tumor protocols and CNS activity)

---

Symptomatic Treatment of Brain Metastases

Symptomatic care may include:

• Corticosteroids to reduce edema and relieve symptoms from increased intracranial pressure (ICP)
• Antiseizure therapy for patients with seizures (and individualized decisions in others)
• management of acute complications (e.g., hemorrhage, hydrocephalus, severe mass effect)

Evidence-based CNS guidelines recommend dexamethasone as the preferred steroid when corticosteroids are used, and emphasize tapering as quickly as clinically tolerated to reduce complications.

Surgical Treatment of Brain Metastases

Surgery may be used to:

• rapidly relieve mass effect,
• obtain tissue diagnosis,
• achieve local control in selected cases (often combined with postoperative radiotherapy).

Guidelines describe surgery as most likely to benefit patients with large tumors causing mass effect and patients whose neurological function can be meaningfully improved.

Surgical removal of brain metastases is performed through a craniotomy, a procedure in which a small opening is made in the skull to access the brain. The goal of surgery is to safely reach the metastasis, relieve pressure on surrounding brain tissue, and remove the tumor when this can provide neurological or diagnostic benefit.

In many cases, brain metastases are well demarcated from normal brain tissue. Unlike infiltrative primary brain tumors, metastases often have a clear boundary, which makes surgical removal technically easier and safer in selected patients. When appropriate and safe, some surgeons also remove a thin margin of surrounding tissue to reduce the risk of local recurrence.

If anatomy and patient condition allow, more than one metastasis may be removed during the same operation, especially when lesions are accessible through the same surgical corridor.

Surgery is performed under the operating microscope, which allows precise visualization and protection of normal brain structures. Modern neurosurgical procedures are supported by several advanced techniques, including:

• Neuronavigation, which helps the surgeon in the OR accurately locate the metastasis and plan the safest surgical trajectory
• Preoperative imaging and surgical planning, including MRI-based planning tailored to each patient
• Diffusion tensor imaging (tractography), used when lesions are close to critical white matter pathways
• Ultrasound guidance, which can help in OR to confirm tumor location and extent during surgery
• Intraoperative neurophysiological monitoring (used selectively), particularly when lesions are near eloquent brain areas responsible for movement or speech

These techniques help maximize tumor removal while minimizing the risk of neurological injury. The decision to operate, and the extent of resection, always depend on tumor location, neurological risk, and the overall treatment strategy defined together with the oncology team.

Read more about potential complications following craniotomy and open brain surgery on this page.

Image: The image illustrates a craniotomy. Both the skin incision and the skull opening are performed within the hair-bearing area of the scalp. The dura is opened to expose the brain as part of the surgical approach to the tumor. After the procedure, the bone flap is secured and the scalp is reconstructed, ensuring no cosmetic defect remains after healing.

Stereotactic Radiosurgery and Radiotherapy in Brain Metastasis

Radiotherapy plays a central role in the treatment of brain metastasis and can be used as a primary treatment, after surgery, or in combination with systemic therapy. The two main approaches—stereotactic radiosurgery (SRS) and whole-brain radiotherapy (WBRT)—differ fundamentally in indication, target volume, dose delivery, and neurocognitive impact.

Stereotactic Radiosurgery (SRS)

Stereotactic radiosurgery delivers a high dose of focused radiation precisely to one or more brain metastases while sparing surrounding normal brain tissue. Despite the term “surgery,” no incision is made.

When SRS is used

• Limited number of brain metastases (commonly 1–4, and in selected patients a higher number, including cases with multiple lesions when cumulative tumor volume is low and systemic disease is well controlled)
• Lesions of relatively small size (typically ≤3–4 cm)
• Metastases located away from critical structures where safe dose delivery is possible
• Postoperative treatment of the surgical cavity after metastasis removal
• Patients with good neurological status and reasonable systemic disease control

Typical dose concepts

• Single-fraction SRS: approximately 18–24 Gy to each metastasis, depending on size and location
• Hypofractionated SRS (delivered over several sessions): used for larger lesions or lesions near critical structures

The key advantage of SRS is high local control with substantially lower risk of cognitive decline compared with whole-brain approaches. Importantly, SRS treats only visible lesions and does not irradiate the entire brain.

Whole-Brain Radiotherapy (WBRT)

Whole-brain radiotherapy delivers radiation to the entire brain, historically based on the assumption that microscopic metastases may already be present but not visible on imaging.

When WBRT is considered

• Widespread intracranial disease, characterized by numerous metastases with a high cumulative tumor burden, where focal treatment would be impractical
• Leptomeningeal metastasis, where diffuse CNS involvement precludes focal therapy
• Rapid intracranial progression, particularly when new lesions develop faster than they can be safely managed with repeated focal treatments
• Situations where repeated SRS is not feasible or has failed, due to cumulative dose constraints or declining neurological status
• Selected palliative scenarios, especially in patients with poor performance status or limited expected survival

Typical dose concepts

• Standard WBRT: 30 Gy in 10 fractions or 20 Gy in 5 fractions, depending on clinical context

Do All Patients Need Whole-Brain Radiotherapy Because of Micrometastases?

No. This is one of the most important shifts in modern practice.

Autopsy and imaging-based studies suggest that microscopic brain metastases likely exist in a substantial proportion of patients with systemic cancer. However, modern evidence shows that prophylactic irradiation of the entire brain does not improve overall survival in most patients with limited brain metastasis and significantly increases the risk of neurocognitive decline.

As a result, current guidelines favor focal treatment (SRS) with close MRI surveillance rather than routine WBRT for patients with limited brain metastasis.

Neurocognitive Toxicity and Brain-Sparing Strategies

WBRT is associated with a risk of:

• memory impairment
• executive dysfunction
• reduced quality of life

To reduce this risk, modern WBRT techniques incorporate hippocampal avoidance, which spares the hippocampal region—an area located deep within the temporal lobe (behind the temples) that is critical for memory formation. This technique is used when there is no metastasis near this structure. Pharmacologic strategies (e.g., memantine) may also be used to mitigate cognitive effects.

How the Choice Is Made in Practice

The decision between SRS and WBRT is individualized and depends on:

• number and size of brain metastases
• anatomical distribution
• risk of neurological deterioration
• patient age and baseline cognitive function
• expected survival based on primary cancer biology
• availability of close imaging follow-up

Modern evidence-based recommendations, including those from ASTRO, emphasize maximizing neurological function and quality of life, not simply radiographic disease control.

Key Clinical Point

Treating all visible brain metastases does not require treating the entire brain.
In many patients, repeated focal treatment with SRS and careful MRI follow-up provides excellent neurological control while avoiding the long-term cognitive toxicity associated with whole-brain irradiation.

Systemic Therapy for Brain Metastases (Expanded Clinical Overview)

Systemic therapy for brain metastases is selected primarily according to the type and biology of the primary cancer, as well as the ability of available treatments to affect tumor cells within the central nervous system (CNS). Unlike local therapies (surgery or radiotherapy), systemic treatments are designed to control microscopic and macroscopic disease throughout the body, including potential disease beyond what is visible on imaging.

Main Categories of Systemic Therapy

Depending on the primary tumor, systemic treatment protocols may include one or more of the following:

1) Conventional Chemotherapy (Cytotoxic Agents)

Traditional chemotherapy drugs (cytostatics) work by damaging rapidly dividing cancer cells. Examples include platinum-based agents, alkylating agents, and antimetabolites.

• BBB penetration:
  Most conventional chemotherapies have limited ability to cross an intact blood–brain barrier (BBB).
• Effect in brain metastases:
  Their activity in the brain is often unpredictable and incomplete, which historically made the brain a “sanctuary site” where cancer could progress despite good systemic control elsewhere.
• Clinical implication:
  Chemotherapy alone is rarely sufficient for symptomatic brain metastases and is usually combined with local treatment.

2) Targeted Therapy

Targeted therapies are drugs designed to block specific molecular pathways or mutations driving cancer growth (e.g., EGFR, ALK, ROS1, BRAF, HER2). A growth signal is sent either by surrounding normal cells or by the tumor cell itself in the form of signaling molecules. These molecules (growth factors or cytokines) bind to receptor proteins on the cell membrane, which then activate intracellular signaling pathways that transmit the message to the nucleus, promoting cell survival and division. This process is amplified in tumor cells because mutations in regulatory genes give them increased autonomy from normal tissue control.

• Examples by tumor type:
  • Lung cancer: EGFR inhibitors, ALK inhibitors, ROS1 inhibitors
  • Breast cancer: HER2-targeted agents
  • Melanoma: BRAF and MEK inhibitors
• BBB penetration:
  Many newer targeted agents have meaningful CNS penetration, especially compared with older drugs.
• Clinical implication:
  In selected patients, targeted therapy can control both systemic disease and brain metastases, sometimes delaying or reducing the need for whole-brain radiotherapy.

3) Immunotherapy

Immunotherapy stimulates the patient’s own immune system—primarily T-lymphocytes, and in some cases antibody-mediated mechanisms—to recognize and attack cancer cells.

• Main classes:
  • Immune checkpoint inhibitors (e.g., PD-1, PD-L1, CTLA-4 inhibitors)
• BBB considerations:
  Immunotherapy does not rely on direct drug penetration in the same way as chemotherapy. Activated immune cells can cross into the CNS and exert antitumor effects.
• Clinical relevance:
  Particularly important in melanoma and certain lung cancers, immunotherapy has significantly improved survival and CNS disease control in selected patients.
• Limitations:
  Response may be reduced in patients requiring high-dose steroids for brain edema.

4) Cellular and Immune-Based Approaches (Emerging Therapies)

In selected cancers and clinical trials, more advanced immune strategies may be used:

• Cancer vaccines involve the administration of tumor-specific antigens that stimulate an active immune response, either humoral (antibody-mediated) or cellular (T-cell-mediated). These antigens may be derived from the patient’s own tumor in personalized approaches or, more commonly, produced using genetic engineering to target antigens characteristic of a specific tumor type.
• Adoptive T-cell therapy (e.g., tumor-infiltrating lymphocytes) involves collecting a patient’s own T-lymphocytes, expanding or activating them in the laboratory, and reinfusing them to enhance the immune attack on the tumor.
• Engineered immune-cell therapies use genetically modified immune cells, such as CAR-T cells, to specifically recognize and destroy cancer cells.

These therapies are not yet standard for most brain metastases, but they reflect ongoing efforts to overcome CNS immune resistance.

---

Blood–Brain Barrier (BBB): Why Some Drugs Work and Others Do Not

The blood–brain barrier normally acts as a highly selective filter, protecting the brain from toxins—but also limiting drug delivery.

Key clinical points:

• In areas of active brain metastases, the BBB is often locally disrupted.
• This disruption creates a “leaky barrier” around the tumor, allowing some systemic drugs to reach metastatic tissue.
• However, BBB disruption is patchy and incomplete, meaning:
  • Drug penetration varies between lesions
  • Microscopic disease may remain protected
• Importantly, normal brain tissue away from metastases still has an intact BBB, limiting drug distribution.

This explains why systemic therapy may shrink some metastases while others persist or why new lesions can appear despite apparent response.

---

Why Systemic Therapy Alone Is Often Not Enough

Despite major advances, current guidelines emphasize several limitations:

• Systemic drugs usually act too slowly to relieve acute neurological emergencies (edema, mass effect, herniation).
• Drug concentrations in the brain may be insufficient or inconsistent.
• Steroids used to control brain edema can reduce the effectiveness of immunotherapy.

For these reasons, symptomatic brain metastases almost always require local treatment (surgery or radiotherapy), with systemic therapy serving as a complementary, not standalone, strategy.

---

Recurrent Brain Metastases

Recurrent brain metastases are common, particularly in patients with longer survival due to effective systemic therapies. Management depends on prior treatments, lesion size and location, cumulative radiation dose, and overall neurological and systemic status. Repeat SRS, surgical resection, or a combination of focal therapies may be appropriate in selected cases, while WBRT is generally reserved for diffuse recurrence or situations where further focal treatment is no longer feasible.

---

Key Clinical Perspective

Systemic therapy plays a crucial role in controlling the underlying cancer and preventing further spread, but local brain treatment remains essential for preserving neurological function and preventing life-threatening complications. The optimal strategy integrates:

• Primary cancer biology and available systemic therapies
• Neurological urgency and symptom burden
• Expected survival and quality-of-life benefit

This integrated approach explains why treatment plans differ widely between patients—and why multidisciplinary decision-making is essential.

---

Prognosis and Survival in Brain Metastases

Prognosis in patients with brain metastases is determined primarily by the biology of the primary cancer, not by brain imaging alone. Even with optimal local control of brain metastases, overall survival usually follows the natural course of the underlying malignancy.

Across large clinical series, median survival after the diagnosis of brain metastases ranges from approximately 3 to 18 months, depending on the primary tumor and systemic disease control.

Primary Tumors with Relatively Longer Survival

Patients with the following cancers tend to live longer, even after brain metastases develop, especially when modern systemic therapy is available:

• Breast cancer: often 12–24 months or longer, particularly in HER2-positive and hormone-receptor-positive subtypes
• Non-small cell lung cancer (NSCLC) with targetable mutations (EGFR, ALK): often 10–20+ months
• Renal cell carcinoma: approximately 8–15 months in selected patients
• Melanoma: historically poor, but with immunotherapy 6–12 months, with a subset of longer survivors

Primary Tumors with Poorer Prognosis

Some cancers exhibit more aggressive biology, where the disease progresses rapidly despite treatment:

• Small-Cell Lung Cancer (SCLC): Typically 3–6 months. While SCLC is highly sensitive to radiation (radiosensitive), it tends to recur quickly and spread aggressively throughout the body.
• Triple-Negative Breast Cancer: Generally has a shorter survival window compared to other breast cancer subtypes due to a lack of targeted receptors.

Factors That Modify Survival

Survival is shorter when there is:

• uncontrolled extracranial disease,
• poor neurological status at presentation,
• widespread intracranial involvement,
• lack of effective systemic therapy.

Survival is longer when:

• the primary cancer is biologically favorable or treatable,
• extracranial disease is controlled,
• effective local brain therapy (surgery and/or stereotactic radiosurgery) is feasible,
• neurological function is preserved.

Key Clinical Point

Successful removal or irradiation of all visible brain metastases does not mean the cancer has been cured.
Local brain control improves neurological function and quality of life, but overall survival is usually dictated by the primary tumor and systemic disease, as assessed by the treating oncologist.

---

In the following sections, we will discuss the specific characteristics of individual types of brain metastases.

Lung Cancer Brain Metastases

Lung cancer is the most common source of brain metastases, accounting for 40–50% of all cases. While Non-Small Cell Lung Cancer (NSCLC) represents 85% of lung cancers, Small-Cell Lung Cancer (SCLC)—only 15% of cases—is responsible for a disproportionately high number of metastases, as over 50% of SCLC patients will develop brain involvement. That is why SCLC is responsible for 25–30% of brain metastases of lung origin.

The treatment approach and operability differ fundamentally between these two types:

SCLC (Small-Cell): These are rarely operated on. Because SCLC is highly radiosensitive (responds rapidly to radiation) and typically presents with diffuse, microscopic spread, the standard of care is radiation (WBRT) or chemotherapy. Surgery is reserved only for exceptional cases, such as a single, large metastasis causing immediate life-threatening brain compression that does not respond to steroids. Despite local control, the prognosis remains poor (3–6 months) due to rapid systemic progression in other organs.

NSCLC (Non-Small Cell): These are the primary candidates for neurosurgical resection, especially when there is a single lesion causing mass effect. In cases with actionable mutations (EGFR, ALK, ROS1), survival often exceeds 12–20 months due to modern drugs with high CNS activity (ability to penetrate the brain).

---

Breast Cancer Brain Metastases

Breast cancer brain metastases are associated with relatively favorable survival compared with many other solid tumors. Account for 15-25% of all brain metastases.
Patients with HER2-positive and hormone-receptor-positive disease often live 12–24 months or longer, reflecting effective modern systemic therapies with CNS activity.
Triple-negative breast cancer is associated with shorter survival, but outcomes still vary widely depending on systemic disease control.

---

Melanoma Brain Metastases

Melanoma is now one of the primary cancers with the best long-term outcomes in selected patients with brain metastases. Account for 5-20% of all brain metastases. Historically, the prognosis was poor, with survival measured in only 6–12 months. However, a major breakthrough in immunotherapy and targeted therapy has shifted the paradigm: as systemic treatments allow patients to live longer, we are seeing an increasing incidence of brain metastases—occurring in up to 40–50% of patients with advanced melanoma.

Due to this improved systemic prognosis, neurosurgical strategy has become more aggressive. We now frequently perform surgical resections even for multiple metastases, especially when combined with Stereotactic Radiosurgery (SRS) for smaller, deep-seated lesions.

While long-term, durable survival is now realistically achievable in a subset of patients, certain factors still limit the outcome:

• Steroid Dependence: Prognosis is worse in patients requiring high-dose steroids (which can interfere with immunotherapy).
• Disease Extent: Outcomes are more guarded with extensive intracranial disease or leptomeningeal involvement.

Despite these challenges, melanoma is no longer considered a disease of uniformly poor prognosis; for many, it has become a manageable condition with the right combination of surgery and modern systemic therapy.

---

Renal Cell Carcinoma Brain Metastases

Renal cell carcinoma brain metastases are often hypervascular and prone to hemorrhage. Account for 5-10% of all brain metastases.
Despite relative radioresistance, patients with limited brain disease and controlled systemic cancer may achieve meaningful survival, commonly in the range of 8–15 months or longer when surgery or stereotactic radiosurgery is feasible.

---

Colorectal Cancer Brain Metastases

Colorectal cancer brain metastases usually occur late in the disease course and are frequently associated with widespread systemic disease. Account for 3-5% of all brain metastases.
As a result, prognosis is often less favorable, with survival commonly measured in months, although selected patients with limited disease and good systemic control may do better.

---

Brain Metastases from an Unknown Primary Tumor

In a substantial proportion of patients, brain metastases are diagnosed before the primary tumor is identified. Account for 20-30% of all brain metastases.
Prognosis in these cases depends on how quickly the primary cancer can be identified and whether it represents a biologically treatable tumor. Outcomes vary widely and cannot be predicted from brain imaging alone.

Frequently Asked Questions About Brain Metastasis